Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/378,617external-prioritypatent/US5849991A/en
Application filed by Bresatec Ltd., St. Vincent's Hospital (Melbourne), LimitedfiledCriticalBresatec Ltd.
Priority claimed from PCT/IB1995/000088external-prioritypatent/WO1995020661A1/en
Publication of MX9603037ApublicationCriticalpatent/MX9603037A/en
Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme 'alpha'-1,3 galactosyltransferase. The porcine gene encoding 'alpha'-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating ("knocking out") the 'alpha'-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the 'alpha'-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.
MX9603037A1995-01-261995-01-27Materials and methods for management of hyperacute rejection in human xenotransplantation.
MX9603037A
(en)
Processes for the isolation, selection and propagation of animal stem cells, genetically modified animals and animal cells, and vectors for the production thereof